Jasper Therapeutics
JSPR
87 hedge funds and large institutions have $335M invested in Jasper Therapeutics in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 14 closing their positions.
147% more call options, than puts
Call options by funds: $6.82M | Put options by funds: $2.76M
100% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 16
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
22% more capital invested
Capital invested by funds: $275M → $335M (+$59.8M)
7% more funds holding
Funds holding: 81 → 87 (+6)
7.18% more ownership
Funds ownership: 97.19% → 104.36% (+7.2%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.29M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$6.25M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.87M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$4.82M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$10.9M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$5.77M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$5.19M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.11M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$1.04M |
JSPR Hedge Fund Activity: Q4 2024 in Review
87 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2024, worth a combined $335M — up 22% from $275M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new JSPR positions and 14 closed out — a net gain of 6 holders — while 32 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $7.29M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $10.9M sold.
- 87 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2024, up from 81 in Q3 2024.
- Funds reported $335M of Jasper Therapeutics stock for Q4 2024, up 22% quarter-over-quarter.
- 20 funds opened new Jasper Therapeutics positions in Q4 2024 and 14 closed out, a net change of +6 holders.
- The largest Jasper Therapeutics buyer in Q4 2024 was Fidelity Investments, an estimated $7.29M added.
- The largest Jasper Therapeutics seller in Q4 2024 was Polar Capital Holdings, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2024.